Kurs & Likviditet
|Lista||First North Stockholm|
|2020-04-21||Ordinarie utdelning INDEX 0.00 SEK|
|2019-10-09||Extra Bolagsstämma 2019|
|2019-05-07||Ordinarie utdelning INDEX 0.00 SEK|
|2018-05-25||Ordinarie utdelning INDEX 0.00 SEK|
|2017-05-31||Ordinarie utdelning INDEX 0.00 SEK|
June 26, 2019 - InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the European Patent Office. The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.
The patent, entitled Method for prevention of colectomy (patent number EP2782602), will provide an exclusivity period until November 2032, with the possibility of up to 5 years term extension after market approval.
"This new patent constitutes a valuable complement to our robust intellectual property portfolio for cobitolimod in Europe," said Peter Zerhouni, CEO of InDex Pharmaceuticals.
Corresponding patent applications were granted in the US in November 2016 and in Japan in August 2017, and a corresponding patent application has been filed in Canada.
For more information:
Peter Zerhouni, CEO
Phone: +46 8 508 847 35
Cobitolimod in brief
Cobitolimod is a Toll-like receptor 9 (TLR9) agonist, that can provide an anti-inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in active ulcerative colitis. Cobitolimod has achieved clinical proof-of-concept in moderate to severe active ulcerative colitis, with a very favorable safety profile. Data from four placebo-controlled clinical trials indicate that cobitolimod has statistically significant effects on those endpoints that are most relevant in this disease, both from a regulatory and clinical perspective. These endpoints include the key clinical symptoms such as blood in stool, number of stools, and mucosal healing, respectively. Based on the encouraging results from earlier studies InDex is now performing the phase IIb study CONDUCT to evaluate higher doses and dose frequencies than investigated in previous studies with cobitolimod. The goal of the study is to optimise the treatment and achieve substantially higher efficacy, while maintaining the compound's excellent safety profile. The CONDUCT study includes 213 patients with left-sided moderate to severe active ulcerative colitis at 91 sites in 12 countries. It is a randomised, double blind, placebo-controlled study for evaluating cobitolimod's efficacy and safety in inducing clinical remission compared to placebo. The dose optimisation study investigates three different dose strengths of cobitolimod and two different dose frequencies. Cobitolimod is also known as Kappaproct® and DIMS0150.
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company's lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
InDex is based in Stockholm, Sweden. The company's shares (ticker INDEX) are traded on Nasdaq First North Stockholm. Redeye AB with email address email@example.com phone number +46 8 121 576 90 is the company's Certified Adviser. For more information, please visit www.indexpharma.com.
This information is information that InDex Pharmaceuticals Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication through the agency of the contact person set out above at 15:50 CET on June 26, 2019.